Overview
Belite Bio reports Q3 net loss of $21.7 mln, increased from $8.7 mln last year
Company completed $15 mln direct offering and $125 mln private placement
China's NMPA and UK's MHRA accept Tinlarebant applications based on DRAGON trial
Outlook
Company expects final DRAGON trial data in Q4 2025
Company anticipates interim analysis for PHOENIX trial
Company aims for regulatory milestones with Tinlarebant
Result Drivers
INCREASED R&D EXPENSES - Driven by costs associated with DRAGON and PHOENIX trials, partially offset by Australian R&D tax incentive
FINANCIAL STRENGTHENING - Completion of $15 mln direct offering and $125 mln private placement enhances financial position
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | -$21.69 mln | ||
Q3 Income From Operations | -$23.02 mln | ||
Q3 Operating Expenses | $23.02 mln | ||
Q3 Pretax Profit | -$21.69 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Belite Bio Inc is $104.00, about 8.8% below its November 7 closing price of $113.19
Press Release: ID:nGNX4z2RCs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)